Skip to main content

Table 2 The Meta-analysis of the prevalence of comorbidities in COVID-19 cases

From: Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and meta-analysis of risk factors

Diseases Pooled prevalence 95% CI I2 P
Hypertension 0.19 0.16–0.22 93.9 < 0.001
Cardiovascular disease 0.06 0.04–0.07 90.5 < 0.001
Diabetes 0.09 0.08–0.11 88.8 < 0.001
COPD 0.03 0.02–0.04 83.0 < 0.001
Cerebrovascular disease 0.03 0.02–0.05 61.4 0.001
Chronic renal disease 0.02 0.01–0.02 51.5 0.004
Chronic liver diseases 0.03 0.02–0.04 72.5 < 0.001
Malignancy 0.01 0.01–0.02 37.8 0.045
  1. Pooled prevalence and 95% confidence intervals (95% CI) of 8 diseases were presented respectively, together with the result of heterogeneity analysis described as I2 and P value. P value for heterogeneity among studies assessed with Cochran’s Q test